Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The nursing team at the Early Phase Clinical Trials Unit has been awarded the Excellence in Cancer Research Nursing Award 2021.

On the 12 October the Royal College of Nursing presented a live-stream ceremony of the RCN Nursing Awards, to recognise the incredible work that nurses undertake every day. 

Amongst this year’s finalists was the Early Phase Clinical Trials Unit (EPCTU) nursing team, based out of the Churchill Hospital, and part of the Oxford University Hospitals NHS Foundation Trust. The team went onto win the Cancer Research UK/Royal College of Nursing Excellence in Cancer Research Nursing Award 2021.

Some members of the Early Phase Clinical Trials Unit (EPCTU) nursing teamSome members of the Early Phase Clinical Trials Unit (EPCTU) nursing team

This team has seen impressive results after its introduction of a mental well-being assessment for early phase trial patients to ensure they were receiving effective and holistic care from the start of their treatment. The team continue to get fantastic feedback from patients, who are often undergoing very difficult times as they partake in clinical trials for cancer treatment. 

The implementation of the assessment has led to numerous referrals to counselling and other services and it has improved communication between patients and staff, allowing them to broach subjects that may otherwise have been unaddressed. The team has streamlined its referral systems since introducing the assessment. Patient feedback has been positive and nurses feel well supported to discuss emotional topics with patients who have no other treatment options left.

In addition, the nurses support and implement the important clinical trials that the unit is known for, running approximately 80 every year, and many of which are the first-in-human trials of innovative cancer treatments. 

 The award was received by Rosie Lomas and her team, and recognises the dedication and hard work the EPCTU Nursing Team put into patient care.


The Early Phase Trials Unit was significantly hit by the pandemic – the trials ward was shut and many staff were deployed to acute medical teams. Despite this, the remaining team members found ingenious ways to continue patients on the trial drugs they needed to keep them alive. 

In addition, by integrating palliative care and introducing wellbeing assessments, they provided greater symptom support and pastoral care to the patients during this extremely difficult time. 

Particular credit should go to Caroline Miles for her benevolent leadership of the nursing team, the nurses themselves and the medics and administrative teams who worked tirelessly alongside them. Well done all!

- Prof.  Sarah Blagden, Oxford’s ECMC lead



Similar stories

Glowing dye helps surgeons eradicate prostate cancer

A glowing marker dye that sticks to prostate cancer cells could help surgeons to remove them in real-time, according to a study led by the University of Oxford.

New funding for development of world's first lung cancer vaccine

Oxford and UCL researchers seeking to create the world’s first vaccine to prevent lung cancer in people at high risk of the disease have been granted up to £1.7 million from Cancer Research UK and the CRIS Cancer Foundation.

Prof Anna Schuh launches first private specialised haematology clinic and laboratory in sub-Saharan Africa.

SerenOx Africa aims to address diagnostic gaps for common blood disorders through a testing facility for key underserved patient populations in Tanzania. This facility will also aim to provide early cancer detection for high-risk patients.

Professor Eileen Parkes appointed to lead Oxford’s Experimental Cancer Medicine Centre

Eileen Parkes, Associate Professor in Innate Tumour Immunology in the Department of Oncology, will lead the expansion of the centre’s programmes in early drug development and biomarker research.

Oxford to launch UK’s first trials unit dedicated to conducting precision prevention and early detection studies

Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.

Multi-cancer blood test shows real promise in NHS trial

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.